Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study
Sponsor: Leonard Appleman
This PHASE1/PHASE2 trial investigates Metastatic Renal Cell Carcinoma and is currently completed. Leonard Appleman leads this study, which shows 11 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Leonard Appleman
- Prometheus Laboratories
For direct contact, visit the study record on ClinicalTrials.gov .